Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

H3B-6545

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eisai

Drug class:

Selective estrogen receptor α inhibitor

Related drugs:

Z-endoxifen (1)

Z-endoxifen (1)

ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2
ER D538G	HER2 Negative Breast Cancer	ER D538G	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2
ER Y537S + ER positive	HER2 Negative Breast Cancer	ER Y537S + ER positive	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C3 – Early Trials H3B-6545 Sensitive : C3	H3B-6545 Sensitive: C3 – Early Trials H3B-6545 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + H3B-6545 Sensitive: C3 – Early Trials palbociclib + H3B-6545 Sensitive : C3	palbociclib + H3B-6545 Sensitive: C3 – Early Trials palbociclib + H3B-6545 Sensitive : C3